NASCOBAL Drug Patent Profile
✉ Email this page to a colleague
When do Nascobal patents expire, and when can generic versions of Nascobal launch?
Nascobal is a drug marketed by Endo Operations and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in NASCOBAL is cyanocobalamin. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nascobal
A generic version of NASCOBAL was approved as cyanocobalamin by PADAGIS ISRAEL on September 9th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NASCOBAL?
- What are the global sales for NASCOBAL?
- What is Average Wholesale Price for NASCOBAL?
Summary for NASCOBAL
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 1 |
| Patent Applications: | 57 |
| Drug Prices: | Drug price information for NASCOBAL |
| Drug Sales Revenues: | Drug sales revenues for NASCOBAL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NASCOBAL |
| What excipients (inactive ingredients) are in NASCOBAL? | NASCOBAL excipients list |
| DailyMed Link: | NASCOBAL at DailyMed |
Recent Clinical Trials for NASCOBAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Swedish Orphan Biovitrum | Phase 1 |
Pharmacology for NASCOBAL
| Drug Class | Vitamin B12 |
Paragraph IV (Patent) Challenges for NASCOBAL
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| NASCOBAL | Nasal Spray | cyanocobalamin | 500 mcg/spray | 021642 | 1 | 2017-04-28 |
US Patents and Regulatory Information for NASCOBAL
NASCOBAL is protected by six US patents.
Patents protecting NASCOBAL
Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NASAL ADMINISTRATION OF CYANOCOBALAMIN
Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NASAL ADMINISTRATION OF CYANOCOBALAMIN
Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Endo Operations | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Endo Operations | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NASCOBAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Operations | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Endo Operations | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Endo Operations | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Endo Operations | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NASCOBAL
See the table below for patents covering NASCOBAL around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
